|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
|
Jul 2020
|
Aging
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Quality of life and physicians' perception in myelodysplastic syndromes
|
May 2012
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Costs and quality of life in patients with myelodysplastic syndromes.
|
Aug 2013
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival
|
Dec 2014
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes
|
Mar 2013
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia.
|
Jun 2013
|
Am J Hematol
|
aplastic anemia
|
|
Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients.
|
Jun 2013
|
Am J Hematol
|
aplastic anemia
|
|
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
|
Mar 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: Contemporary review and how we treat
|
Jan 2016
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
